Sponsor:
Université de Sherbrooke
Code:
NCT06843148
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Liver Fibrosis/NASH
Non-Alcoholic Steato-Hepatitis (NASH)
Eligibility Criteria
Sex: All
Age: 20 - 70+
Healthy Volunteers: Not accepted
Interventions
Niacin (250mg)
Placebo Oral Tablet
Brief summary:
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Liver Fibrosis/NASH
Non-Alcoholic Steato-Hepatitis (NASH)
Study ID
NCT06843148
Start date
Jun 22, 2026
Status verified date
Jun, 2026
Completion date
Jul, 2030
Anticipated
Primary completion date
Mar, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 20 - 70+
Healthy Volunteers: Not accepted
Enrollment
36 participants
Anticipated
Allocation
Randomized
Intervention Model
Crossover
Primary purpose
Basic Science
Arms
placebo comparator: Placebo group
active comparator: Niacin group
Interventions
Niacin (250mg)
Placebo Oral Tablet
Primary outcome measure
Central contacts
Locations
Centre de recherche du CHUS
Recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contacts
Sponsor
Université de Sherbrooke
Last update posted
Jul 2, 2026
Last verified
Jun, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Université de Sherbrooke on 2026-07-02.